NMPA Guidance on the Management of Clinical Trials during the COVID-19 from July 2020

August 20, 2020

Conducting clinical trials during the COVID-19 pandemic has produced many challenges globally. The initiation, conduct, implementation and completion of a trial during this time requires special considerations. Read more in our latest blog.

Previous Article
The Special Approval Pathway (SAP) for COVID-19 related products in China
The Special Approval Pathway (SAP) for COVID-19 related products in China

Since the COVID-19 pandemic began in early 2020, the Center for Drug Evaluation (CDE) has maximized its cap...

Next Article
GxP On-Site Inspections are Restarting: Preparing for inspections under the “new normal”
GxP On-Site Inspections are Restarting: Preparing for inspections under the “new normal”

With the continued threat of COVID-19, the way inspections will be performed and hosted will be significant...